{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:10:24Z","timestamp":1787292624955,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T00:00:00Z","timestamp":1435104000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10067-015-2991-1","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T01:43:03Z","timestamp":1435023783000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"given":"Shaobo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"issue":"4","key":"2991_CR1","first-page":"925","volume":"59","author":"MD Harris","year":"1999","unstructured":"Harris MD, Siegel LB, Alloway JA (1999) Gout and hyperuricemia. Am Fam Physician 59(4):925\u2013934","journal-title":"Am Fam Physician"},{"issue":"3","key":"2991_CR2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002512-199813030-00006","volume":"13","author":"AG Fam","year":"1998","unstructured":"Fam AG (1998) Gout in the elderly. Clinical presentation and treatment. Drugs Aging 13(3):229\u2013243","journal-title":"Drugs Aging"},{"issue":"5","key":"2991_CR3","first-page":"242","volume":"18","author":"S Garcia-Mendez","year":"2012","unstructured":"Garcia-Mendez S, Beas-Ixtlahuac E, Hernandez-Cuevas C et al (2012) Female gout: age and duration of the disease determine clinical presentation. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 18(5):242\u2013245","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"2","key":"2991_CR4","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28. doi: 10.1186\/ar2143","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2991_CR5","first-page":"1232","volume":"54","author":"TJ Buckley","year":"1996","unstructured":"Buckley TJ (1996) Radiologic features of gout. Am Fam Physician 54(4):1232\u20131238","journal-title":"Am Fam Physician"},{"issue":"2","key":"2991_CR6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0889-857X(21)00969-8","volume":"14","author":"RA Terkeltaub","year":"1988","unstructured":"Terkeltaub RA, Ginsberg MH (1988) The inflammatory reaction to crystals. Rheum Dis Clin N Am 14(2):353\u2013364","journal-title":"Rheum Dis Clin N Am"},{"issue":"6","key":"2991_CR7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(98)00323-4","volume":"105","author":"RL Wortmann","year":"1998","unstructured":"Wortmann RL (1998) Effective management of gout: an analogy. Am J Med 105(6):513\u2013514","journal-title":"Am J Med"},{"issue":"10","key":"2991_CR8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64(10):1447\u20131461","journal-title":"Arthritis Care Res"},{"issue":"7352","key":"2991_CR9","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","volume":"324","author":"HR Schumacher Jr","year":"2002","unstructured":"Schumacher HR Jr, Boice JA, Daikh DI et al (2002) Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ (Clin Res ed) 324(7352):1488\u20131492","journal-title":"BMJ (Clin Res ed)"},{"issue":"7","key":"2991_CR10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kem090","volume":"46","author":"RE Willburger","year":"2007","unstructured":"Willburger RE, Mysler E, Derbot J, Jung T et al (2007) Lumiracoxib 400\u00a0mg once daily is comparable to indomethacin 50\u00a0mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford, England) 46(7):1126\u20131132","journal-title":"Rheumatology (Oxford, England)"},{"issue":"9","key":"2991_CR11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3899\/jrheum.110916","volume":"39","author":"HR Schumacher","year":"2012","unstructured":"Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F et al (2012) Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 39(9):1859\u20131866","journal-title":"J Rheumatol"},{"issue":"2","key":"2991_CR12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0022-3565(24)38776-2","volume":"296","author":"D Riendeau","year":"2001","unstructured":"Riendeau D, Percival MD, Brideau C, Charleson S et al (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296(2):558\u2013566","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2991_CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079902125000282","volume":"18","author":"AT Leung","year":"2002","unstructured":"Leung AT, Malmstrom K, Gallacher AE, Sarembock B et al (2002) Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 18(2):49\u201358","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2991_CR14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2036.1997.154330000.x","volume":"11","author":"MT Donnelly","year":"1997","unstructured":"Donnelly MT, Hawkey CJ (1997) Review article: COX-II inhibitors\u2014a new generation of safer NSAIDs? Aliment Pharmacol Ther 11(2):227\u2013236","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"2991_CR15","first-page":"Si31","volume":"69","author":"DA Peura","year":"2002","unstructured":"Peura DA (2002) Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med 69(Suppl 1):Si31\u2013Si39","journal-title":"Cleve Clin J Med"},{"issue":"Suppl 1","key":"2991_CR16","first-page":"Si40","volume":"69","author":"JM Scheiman","year":"2002","unstructured":"Scheiman JM (2002) Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 69(Suppl 1):Si40\u2013Si46","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"2991_CR17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20(3):895\u2013900","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2991_CR18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","volume":"50","author":"BR Rubin","year":"2004","unstructured":"Rubin BR, Burton R, Navarra S, Antigua J et al (2004) Efficacy and safety profile of treatment with etoricoxib 120\u00a0mg once daily compared with indomethacin 50\u00a0mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 50(2):598\u2013606","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2991_CR19","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3760\/cma.j.issn.0366-6999.20122892","volume":"126","author":"T Li","year":"2013","unstructured":"Li T, Chen SL, Dai Q, Han XH et al (2013) Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial. Chin Med J 126(10):1867\u20131871","journal-title":"Chin Med J"},{"issue":"4","key":"2991_CR20","first-page":"451","volume":"17","author":"JL Lu","year":"2014","unstructured":"Lu JL (2014) Clinical efficacy of etoricoxib in the treatment of acute gouty arthritis. Pract Pharm Clin Remedies 17(4):451\u2013453","journal-title":"Pract Pharm Clin Remedies"},{"issue":"4","key":"2991_CR21","first-page":"391","volume":"8","author":"Q Ye","year":"2010","unstructured":"Ye Q, Du PF, Wang ZZ et al (2010) Effect of etoricoxib on acute gout. Clin Educ Gen Pract 8(4):391\u2013393","journal-title":"Clin Educ Gen Pract"},{"issue":"29","key":"2991_CR22","first-page":"5747","volume":"14","author":"M Guo","year":"2014","unstructured":"Guo M, Cheng ZF, Hu YH et al (2014) Evaluation of efficacy of COX-2 inhibitors in the treatment of patients with acute gouty arthritis. Prog Mod Biomed 14(29):5747\u20135750","journal-title":"Prog Mod Biomed"},{"issue":"5","key":"2991_CR23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1182\/blood.V91.5.1769","volume":"91","author":"M Pouliot","year":"1998","unstructured":"Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG (1998) Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 91(5):1769\u20131776","journal-title":"Blood"},{"issue":"18","key":"2991_CR24","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2165\/00003495-200262180-00006","volume":"62","author":"DJ Cochrane","year":"2002","unstructured":"Cochrane DJ, Jarvis B, Keating GM (2002) Etoricoxib. Drugs 62(18):2637\u20132651, discussion 2652\u20132633","journal-title":"Drugs"},{"issue":"3 Suppl","key":"2991_CR25","first-page":"S18","volume":"10","author":"HR Schumacher Jr","year":"2004","unstructured":"Schumacher HR Jr (2004) Management strategies for osteoarthritis, ankylosing spondylitis, and gouty arthritis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 10(3 Suppl):S18\u2013S25","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"11","key":"2991_CR26","first-page":"1","volume":"12","author":"YF Chen","year":"2008","unstructured":"Chen YF, Jobanputra P, Barton P, Bryan S et al (2008) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess (Winchester, England) 12(11):1\u2013278","journal-title":"Health Technol Assess (Winchester, England)"},{"issue":"12","key":"2991_CR27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/17425255.2012.741120","volume":"8","author":"RJ Lories","year":"2012","unstructured":"Lories RJ (2012) Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol 8(12):1599\u20131608","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"2991_CR28","first-page":"345","volume":"59","author":"P Leclercq","year":"2004","unstructured":"Leclercq P, Malaise MG (2004) Etoricoxib (arcoxia). Rev Med Liege 59(5):345\u2013349","journal-title":"Rev Med Liege"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-2991-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2991-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T20:12:24Z","timestamp":1748463144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-2991-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-2991-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,24]]}}}